Dr. Cheng is the Founder and Chief Executive Officer (CEO) of AllClev Tech, Inc.  He holds an M.D and a Ph.D. and is the sole inventor of several U.S. patent-pending innovative artificial intelligence (AI) technologies designed for healthcare, medical applications, clinical research, human needs, and beyond. 

Prior to founding AllClev Tech, Inc., he was Senior Vice President (SVP) of Translational Medicine at a small to mid-sized biopharmaceutical company. He also held leadership positions across Immunology, Molecular Biology, Clinical Development and Medical Operations at Thermo Fisher Scientific, a global leader in biotechnology.

Before joining Thermo Fisher Scientific, Dr. Cheng held a faculty position specializing in immunomodulation, immune tolerance induction for organ transplantation in the Department of Surgery at University of Maryland School of Medicine and was actively involved in cancer research in Greenebaum Comprehensive Cancer Center at the same university. With over 25 years of experience, his expertise spans clinical research, drug development, R&D, preclinical study and  translational medicine in various areas, including drug development lifecycle management, cancers, vaccines, neurology, immunotherapy, cell therapy, gene therapy, organ transplantation, stem cell, anti-aging, cardiovascular diseases, immunology, immunomodulation, biochemistry, cell and molecule biology. Dr. Cheng has authored more than 90 publications.

Dr. Cheng conducted post-doctoral research in Biochemistry and Molecular Biology at Northwestern University in Chicago, IL, USA, and additionally in Biochemistry at Umeå University in Sweden. His Ph.D. in Biochemistry was awarded by Umeå University, and M.D was awarded by Nanchang University Medical School.